Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free VIRX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Viracta Therapeutics (VIRX) Competitors

Viracta Therapeutics logo
Compare

VIRX vs. ABP, ASLN, ASBP, CERO, and EVFM

Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Abpro (ABP), ASLAN Pharmaceuticals (ASLN), Aspire Biopharma (ASBP), CERo Therapeutics (CERO), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry.

How does Viracta Therapeutics compare to Abpro?

Abpro (NASDAQ:ABP) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Abpro is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbproN/AN/A-$7.23M-$4.23N/A
Viracta TherapeuticsN/AN/A-$51.06M-$1.10N/A

23.3% of Abpro shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Abpro's return on equity of 0.00% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AbproN/A N/A -344.76%
Viracta Therapeutics N/A -1,899.61%-114.21%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abpro
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Viracta Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Abpro had 1 more articles in the media than Viracta Therapeutics. MarketBeat recorded 1 mentions for Abpro and 0 mentions for Viracta Therapeutics. Abpro's average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score.

Company Overall Sentiment
Abpro Neutral
Viracta Therapeutics Neutral

Summary

Abpro beats Viracta Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Viracta Therapeutics compare to ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

ASLAN Pharmaceuticals has higher revenue and earnings than Viracta Therapeutics. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Viracta TherapeuticsN/AN/A-$51.06M-$1.10N/A

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Viracta Therapeutics' return on equity of -1,899.61% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Viracta Therapeutics N/A -1,899.61%-114.21%

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Viracta Therapeutics Neutral

Summary

Viracta Therapeutics beats ASLAN Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Viracta Therapeutics compare to Aspire Biopharma?

Aspire Biopharma (NASDAQ:ASBP) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aspire Biopharma has higher revenue and earnings than Viracta Therapeutics. Aspire Biopharma is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aspire Biopharma$10K92.87-$24.48M-$20.00N/A
Viracta TherapeuticsN/AN/A-$51.06M-$1.10N/A

In the previous week, Aspire Biopharma had 1 more articles in the media than Viracta Therapeutics. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for Viracta Therapeutics. Viracta Therapeutics' average media sentiment score of 0.00 beat Aspire Biopharma's score of -1.00 indicating that Viracta Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aspire Biopharma Negative
Viracta Therapeutics Neutral

Aspire Biopharma has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Viracta Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aspire Biopharma's return on equity of 0.00% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aspire BiopharmaN/A N/A -1,468.13%
Viracta Therapeutics N/A -1,899.61%-114.21%

Summary

Viracta Therapeutics beats Aspire Biopharma on 7 of the 12 factors compared between the two stocks.

How does Viracta Therapeutics compare to CERo Therapeutics?

Viracta Therapeutics (NASDAQ:VIRX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Viracta Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/A-$51.06M-$1.10N/A
CERo TherapeuticsN/AN/A-$8.30M-$102.61N/A

In the previous week, Viracta Therapeutics' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Viracta Therapeutics Neutral
CERo Therapeutics Neutral

Viracta Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

CERo Therapeutics has a consensus price target of $45.00, indicating a potential upside of 153,483.62%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Viracta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viracta Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

CERo Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viracta TherapeuticsN/A -1,899.61% -114.21%
CERo Therapeutics N/A N/A -209.40%

Summary

Viracta Therapeutics and CERo Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Viracta Therapeutics compare to Evofem Biosciences?

Viracta Therapeutics (NASDAQ:VIRX) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evofem Biosciences has higher revenue and earnings than Viracta Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/A-$51.06M-$1.10N/A
Evofem Biosciences$11.39M0.08$52.98M-$0.03N/A

In the previous week, Viracta Therapeutics' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
Viracta Therapeutics Neutral
Evofem Biosciences Neutral

Viracta Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the S&P 500.

Viracta Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viracta TherapeuticsN/A -1,899.61% -114.21%
Evofem Biosciences -46.42%-91.97%-61.93%

Summary

Viracta Therapeutics and Evofem Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

Get Viracta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIRX vs. The Competition

Export
MetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$389K$897.39M$6.18B$12.29B
Dividend YieldN/A4.84%2.78%5.24%
P/E Ratio-0.011.7128.7327.27
Price / SalesN/A122.44507.2964.11
Price / CashN/A20.0743.3053.97
Price / Book0.037.7110.006.83
Net Income-$51.06M-$5.06M$3.54B$332.87M

Viracta Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIRX
Viracta Therapeutics
N/A$0.01
flat		N/AN/A$389KN/AN/A20
ABP
Abpro
0.0305 of 5 stars		$0.52
flat		N/AN/A$1.42MN/AN/A15
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30
ASBP
Aspire Biopharma
0.5086 of 5 stars		$0.24
+16.9%		N/AN/A$1.23M$10KN/AN/A
CERO
CERo Therapeutics
0.8724 of 5 stars		$0.03
+3.6%		$45.00
+141,409.4%		-99.8%$1.17MN/AN/A8

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VIRX) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel